Metabonomics uncovers a reversible proatherogenic lipid profile during infliximab therapy of inflammatory bowel disease
Pre-publication versions of this article are available by contacting email@example.com.
|30 May 2017||Submitted||Original manuscript|
|16 Jul 2017||Reviewed||Reviewer Report - Parakkal Deepak|
|17 Jul 2017||Reviewed||Reviewer Report - Afsaneh Oskouie|
|26 Jul 2017||Reviewed||Reviewer Report - Peter Adriaensens|
|25 Aug 2017||Author responded||Author comments - jacob bjerrum|
|Resubmission - Version 2|
|25 Aug 2017||Submitted||Manuscript version 2|
|10 Sep 2017||Reviewed||Reviewer Report - Peter Adriaensens|
|16 Sep 2017||Reviewed||Reviewer Report - Afsaneh Oskouie|
|21 Sep 2017||Reviewed||Reviewer Report - Parakkal Deepak|
|27 Sep 2017||Author responded||Author comments - jacob bjerrum|
|Resubmission - Version 3|
|27 Sep 2017||Submitted||Manuscript version 3|
|29 Sep 2017||Editorially accepted|
|16 Oct 2017||Article published||10.1186/s12916-017-0949-7|
How does Open Peer Review work?
Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article are available by contacting firstname.lastname@example.org.
You can find further information about the peer review system here.